Integra LifeSciences Holdings Corporation (IART)

Integra LifeSciences' stock experienced a 26.06% decline from October 2024 to October 2025. In Q1 2025, revenue was $383 million, but organic revenue decreased by 3.5%. Adjusted EPS was $0.41. Q2 2025 revenue beat estimates by 5%. In July 2025, the company recalled MicroMyst Applicators due to sterilization concerns. In September 2025, Dr. Raymond Turner was appointed as the new corporate vice president and chief medical officer. Citigroup maintained a "Sell" recommendation for IART stock in October 2025.

Integra LifeSciences' management anticipates seasonal demand increases to contribute to recovery in the second half of 2025, indicating some level of demand seasonality for its products and services.

Integra LifeSciences Holdings Corp. operates in the Health Care sector, focusing on Medical/Dental Instruments and Medical Specialties. It has two segments: Codman Specialty Surgical (CSS), which offers products for neurosurgery, neurocritical care, and otolaryngology, and Tissue Technologies (TT), which focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. Key products include Integra artificial skin, DuraGen, and PriMatrix.

Integra LifeSciences has a strong global presence with offices and manufacturing facilities in Asia, Australia, Europe, the Middle East, and the Americas. Its products are sold in over 120 countries, and the company is headquartered in Princeton, New Jersey, U.S.

Integra LifeSciences received positive recognition as a top 100 leader in healthcare technology for 2024 and one of America's best employers for 2025. It was also included on Medical Design & Outsourcing's 2025 MedTech Big 100 list for the fifth consecutive year in September 2025. However, the recall of MicroMyst Applicators in July 2025 due to sterilization concerns could have negatively impacted its brand reputation.

Integra LifeSciences Holdings Corp. has a mixed ownership structure, with approximately 93.86% of the stock held by institutional shareholders such as BlackRock, Inc., Vanguard Group Inc, and Rubric Capital Management LP. Richard E. Caruso, the company's founder, is the largest individual shareholder, owning 21.35 million shares, representing 27.40% of the company.